10
Participants
Start Date
March 31, 2012
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
Ranolazine
Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
Matching placebo
Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
Oklahoma City VA Medical Center, Oklahoma City
OU Medical Center, Oklahoma City
Collaborators (1)
Gilead Sciences
INDUSTRY
University of Oklahoma
OTHER